摘要
目的:探讨表皮生长因子受体(EGFR),生存素(Survivin)和尿激酶型纤溶酶原激活剂(uPA)在乳腺良、恶性肿瘤表达的意义和它们的相关性。方法:利用PV免疫组织化学方法,检测88例乳腺癌和32例乳腺腺瘤中EGFR,Survivin和uPA阳性率。结果:乳腺腺瘤和乳腺癌EGFR阳性率分别为18.75%和63.64%,两者差异有统计学意义(P<0.01);Survivin在乳腺腺瘤和乳腺癌阳性率分别为65.62%和70.45%;uPA在乳腺腺瘤和乳腺癌阳性率分别为31.25%和61.36%,两者差异有统计学意义(P<0.05)。EGFR,Survivin和uPA在分期低(Ⅰ、Ⅱ期)、非浸润型和无转移组阳性率均低于分期高(Ⅲ、Ⅳ期)、浸润型癌和有淋巴结转移组(P<0.05)。结论:EGFR、Survivin和uPA在乳腺癌中表达率较高,而且和乳腺癌的生物学特性有关。检测它们对提示预后和靶向治疗有指导意义。
Objective：To explore the significances of epidermal growth factor receptor （EGFR）, Survivin and urokinase-type plasminogen activator （uPA） expressions in benign and malignant breast tumors and their correlation.Methods：PV immunohistochemical method was used to detect the positive rates of EGFR, Survivin and uPA in 88 cases with breast cancer and 32 cases with breast adenoma.Results：The positive rates of EGFR in breast adenoma and breast cancer were 18.75% and 63.64%, respectively, there was significant difference （P〈0.01）.The positive rates of Survivin in breast adenoma and breast cancer were 65.62% and 70.45%, respectively; the positive rates of uPA in breast adenoma and breast cancer were 31.25% and 61.36%, respectively, there was significant difference （P〈0.05）.The positive rates of EGFR, Survivin and uPA in low grades （Ⅰ,Ⅱ）, non-infiltration and not-metastasis group were lower than those in high grades （Ⅲ,Ⅳ）, infiltration and metastasis group （P〈0.05）.Conclusion：The expression rates of EGFR, Survivin and uPA are high in breast cancer, which are related to biological characteristics of breast cancer; detection of EGFR, Survivin and uPA has guiding significance for predicting prognosis and targeted therapy.
出处
《中国妇幼保健》
CAS
北大核心
2010年第35期5297-5299,共3页
Maternal and Child Health Care of China
基金
张家口科技局科研项目〔061158〕
关键词
表皮生长因子受体
生存素
尿激酶型纤溶酶原激活剂
乳腺癌
Epidermal growth factor receptor
Survivin
Urokinase -type plasminogen activator
Breast cancer
